205 related articles for article (PubMed ID: 16760272)
1. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.
Ciardiello F; Troiani T; Bianco R; Orditura M; Morgillo F; Martinelli E; Morelli MP; Cascone T; Tortora G
Ann Oncol; 2006 Jun; 17 Suppl 7():vii109-14. PubMed ID: 16760272
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for advanced non-small cell lung cancer.
Starakis I; Nikolakopoulos A; Mazokopakis EE
Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
[TBL] [Abstract][Full Text] [Related]
4. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
[TBL] [Abstract][Full Text] [Related]
5. Evolving molecular-based targeted therapy for cancer: an exciting field.
Carneiro B; Hsiao K; Khandekar J
Compr Ther; 2005; 31(4):299-305. PubMed ID: 16407611
[TBL] [Abstract][Full Text] [Related]
6. A Third Shot at EGFR: New Opportunities in Cancer Therapy.
Guardiola S; Varese M; Sánchez-Navarro M; Giralt E
Trends Pharmacol Sci; 2019 Dec; 40(12):941-955. PubMed ID: 31706618
[TBL] [Abstract][Full Text] [Related]
7. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
[TBL] [Abstract][Full Text] [Related]
8. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.
Caraglia M; Santini D; Bronte G; Rizzo S; Sortino G; Rini GB; Di Fede G; Russo A
Curr Drug Metab; 2011 Dec; 12(10):944-55. PubMed ID: 21787268
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
Byers LA; Heymach JV
Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S79-85. PubMed ID: 17382029
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
11. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
12. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
Langer C; Soria JC
Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
Hoffmann S; Burchert A; Wunderlich A; Wang Y; Lingelbach S; Hofbauer LC; Rothmund M; Zielke A
Endocrine; 2007 Apr; 31(2):105-13. PubMed ID: 17873319
[TBL] [Abstract][Full Text] [Related]
14. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
15. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted therapy for gastrointestinal cancer.
Wiedmann MW; Caca K
Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
[TBL] [Abstract][Full Text] [Related]
18. Past, present and future of targeted therapy in solid tumors.
Palazzo A; Iacovelli R; Cortesi E
Curr Cancer Drug Targets; 2010 Aug; 10(5):433-61. PubMed ID: 20384576
[TBL] [Abstract][Full Text] [Related]
19. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
20. Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathways.
Liang W; Zheng Y; Zhang J; Sun X
BMC Bioinformatics; 2019 May; 20(Suppl 7):203. PubMed ID: 31074391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
